TP53 and ovarian carcinoma: reported that HSP90 can attenuate the degradation of mutant p53, and HSP90 inhibition can prolong survival in a conditional inactivatable p53R248Q (floxQ) mice model by promoting mutant p53 degradation.[32] Another study reported that the MCB613 is a promising inhibitor, which suppressed ovarian cancer cells by driving p53R175H nuclear export and promoting p53R175H degradation by lysosome.[21] Our results indicate that inhibiting LACTBM5L+R469K has similar effects compared with MCB613 and suggest that LACTBM5L+R469K inhibition is a reliable means of depleting mutant p53R156P protein.